Peringatan Keamanan

Symptoms of overdose include excitation and convulsions.

Methyprylon

DB01107

small molecule approved illicit withdrawn

Deskripsi

Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia. However, with the introduction of newer drugs with fewer side effects, such as benzodiazepines, the clinical use of methyprylon is now limited. Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.

Struktur Molekul 2D

Berat 183.2475
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 6-16 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic. Methyprylon is almost completely metabolized.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

665 Data
Buprenorphine Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Hydrocodone Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Magnesium sulfate The therapeutic efficacy of Methyprylon can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Methyprylon may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Mirtazapine Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Orphenadrine Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Pramipexole Methyprylon may increase the sedative activities of Pramipexole.
Ropinirole Methyprylon may increase the sedative activities of Ropinirole.
Rotigotine Methyprylon may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Methyprylon.
Suvorexant Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Thalidomide Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Methyprylon.
Sodium oxybate Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Ethanol Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Fluvoxamine The risk or severity of adverse effects can be increased when Methyprylon is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Methyprylon is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Methyprylon is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Methyprylon is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Methyprylon is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Methyprylon is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Methyprylon is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Methyprylon is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Methyprylon is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Methyprylon is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Methyprylon is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Methyprylon is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Methyprylon is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Methyprylon is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Methyprylon is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Methyprylon is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Methyprylon is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Methyprylon.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Methyprylon.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Methyprylon.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Methyprylon.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Methyprylon.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Methyprylon.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Methyprylon.
Doxepin The risk or severity of CNS depression can be increased when Methyprylon is combined with Doxepin.
Desipramine The risk or severity of CNS depression can be increased when Methyprylon is combined with Desipramine.
Pizotifen The risk or severity of CNS depression can be increased when Methyprylon is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Methyprylon is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Methyprylon is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Methyprylon.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Methyprylon.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Methyprylon.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Methyprylon.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Methyprylon.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Methyprylon.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Methyprylon.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Methyprylon.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Methyprylon.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Methyprylon.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Methyprylon.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Methyprylon.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Methyprylon.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Methyprylon.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Methyprylon.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Methyprylon.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Methyprylon.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Methyprylon.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Methyprylon.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Methyprylon.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Methyprylon.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Methyprylon.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Methyprylon.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Methyprylon.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Methyprylon.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Methyprylon.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Methyprylon.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Methyprylon.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Methyprylon.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Methyprylon.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Methyprylon.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Methyprylon.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Methyprylon.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Methyprylon.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Methyprylon.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Methyprylon.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Methyprylon.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Methyprylon.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Methyprylon.
Sulpiride The risk or severity of CNS depression can be increased when Sulpiride is combined with Methyprylon.
Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Methyprylon.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Methyprylon.

Target Protein

GABA(A) Receptor GABRA1
Gamma-aminobutyric acid receptor subunit alpha-1 GABRA1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 1686463
    Contos DA, Dixon KF, Guthrie RM, Gerber N, Mays DC: Nonlinear elimination of methyprylon (noludar) in an overdosed patient: correlation of clinical effects with plasma concentration. J Pharm Sci. 1991 Aug;80(8):768-71.
  • PMID: 2866242
    Gwilt PR, Pankaskie MC, Thornburg JE, Zustiak R, Shoenthal DR: Pharmacokinetics of methyprylon following a single oral dose. J Pharm Sci. 1985 Sep;74(9):1001-3.
  • PMID: 16792
    Lomen P, Linet OI: Hypnotic efficacy of triazolam and methyprylon ininsomniac in-patients. J Int Med Res. 1976;4(1):55-8.

Contoh Produk & Brand

Produk: 0 • International brands: 3
International Brands
  • Dimerin
  • Noctan
  • Noludar

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul